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The First Workshop of the European Consortium on Charcot-Marie-Tooth (CMT) disease brought 
together neuroscientists, molecular and cell biologists, neuropathologists, neurologists, and geneti­
cists with a common interest in the understanding of the fundamental mechanisms that underlie the 
pathogenesis of CMT. The interdisciplinary group of 25 expert scientists discussed recent advances in 
(i) molecular genetics and histopathology of CMT, (ii) development of suitable animal models, (rii) 
understanding of the cellular function of CMT-related proteins, and (iv) studies using nerve biopsies 
from CMT patients. In this minireview, we summarize the key findings presented and discuss their
impact on CMT research. © 1997 Academic Press
GENETICS AND HISTOPATHOLOGY
Molecular genetics
CMT1 is genetically heterogeneous and has been 
shown to be associated with at least four distinct 
chromosomal loci, providing the genetic rationale for a 
classification of CMT1 disease forms (for review see De 
Jonghe et al, 1997). CMT'l genes have been identified 
on chromosomes 17 (CMT1A, hereditary neuropathy
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with liability to pressure palsies (HNPP)), 1 (CMT1B), 
and X (CMTX). The most common form, CMT1A, is 
predominantly associated with a 1.5~Mb diiplication 
that appears to arise from unequal recombination at 
repeat sequences of insect origin and includes the gene 
of the peripheral myelin protein PMP22 (Suter & 
Snipes, 1993). Deletion of the same chromosomal 
region that is duplicated in CMT1A is the most 
frequent genetic defect causing HNPP. The duplication 
and deletion frequencies in CMT1 or HNPP patients 
were estimated by the European CMT Consortium to 
be approximately 71 and 84%, respectively (Nelis et al.,
1996).
Thus far, 12 point mutations (9 missense, 1 frame 
shift, and 2 splice site mutations) have been identified
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within regions of the PMP22 gene that encode poten­
tial transmembrane domains giving rise to three dis­
tinct disease phenotypes (CMT1 A, Dejerine-Sottas Syn­
drome (DSS) and HNPP). Thirty-six different mutations 
(25 mtssense, 3 nonsense, 5 frame shift, and 3 deletion 
mutations) within the major myelin protein Po (MPZ) 
gene on chromosome 1 have been linked to CMT1B (28 
mutations), DSS (7 mutations), and congenital hypomy- 
elination (1 mutation). The extracellular domain of the 
Po protein is predominantly but not exclusively, af­
fected (Warner et al., 1996).
Genetically, DSS appears not to be a distinct disease 
entity, but is rather caused by mutations of either the 
PMP22 or the Po gene (V. Timmerman). In CMTX, 58 
different mutations were found within the coruiexin32 
(Cx32; GJB1) gene, comprising 43 missense, 7 non­
sense, 4 frame shift, 2 deletion, and 2 combined 
deletion-frame shift mutations (E. Nelis). Other inves­
tigators have collected more than 80 mutations within 
the coding region of Cx32 (Scherer et al, 1997). N. 
Haites reported on the interesting finding that 10 of 36 
analyzed X-linked CMT families carried noncoding 
region mutations. Thus far, mutations were detected 
(a) in the 5'-untranslated region of exon IB, creating a 
potential donor splice site or a translational start site, 
and (b) in the P2-promoter region of Cx32, possibly 
altering the rate of transcription (Sohl et al, 1996). By 
analogy, it is anticipated that noncoding region muta­
tions in the PMP22 and/or Po genes might also occur 
in CMT1A and CMT1B families.
In addition to CMT1, rare CMT forms including 
recessive CMT4 (recessive HMSN), CMT2A-D (HMSN
II), axonal motor-sensory neuropathy with deafness 
and mental retardation (CMT2X), the spinal form of 
CMT (HMN II, V), hereditary neuralgic amyotrophy 
(HNA), and hereditary sensory neuropathy (HSN I,
III) have been linked to at least 15 different chromo­
somal loci (V. Timmerman).
Histopathology
In CMT1A sural nerve biopsies, the profile of myelin­
ated fibers generally indicates that a significant propor­
tion of large and small myelinated fibers are lost. 
However, there are remarkable differences between 
patients with a PMP22 duplication and those carrying 
point mutations with respect to g-ratio, total trans­
verse fascicular area (TTFA), and onset and degree of 
onion bulb formation in young patients (point 
mutations»  duplication; A. Gabreels-Festen, M. 
Schröder; Gabreels-Festen etal, 1995). The morphologi­
cal criteria for HNPP include tomacula, some de- and
remyelination leading to a few onion bulbs, variable 
axon loss, and normal g-ratio of myelinated fibers 
(Windebank, 1993). However, similar to CMT1A, the 
phenotype of HNPP frame-shifting mutations in PMP22 
differs from the deletion phenotype with respect to the 
amount of onion bulbs and increase in TTFA (point 
mutations »  deletion). On the other hand, CMT1B 
could clearly be divided into two morphologically 
distinct groups, one group featuring mainly uncom­
pacted myelin and the other group containing many 
focally folded myelin sheaths (A. Gabreels-Festen). In 
some CMT1B sural nerve biopsies, the frequency of 
tomacula was even higher than in HNPP It will be 
fascinating to determine whether morphologically dis­
tinct phenotypes can be correlated with specific posi­
tions of mutations in the Po gene. Even in CMT1 A, rare 
tomacula can be found. Thus, it became evident that 
morphological criteria seem to be less reliable in 
CMT1A, CMT1B, and HNPP than previously antici­
pated and the suggestion was made to also include 
motor nerve autopsies of genetically diagnosed pa­
tients into morphological analyses. Furthermore, it 
was pointed out that part of the variability observed in 
the morphological spectrum of CMT1A (e.g., in myelin­
ated axon profiles) may be due to age-dependent 
alterations (M. Schroder; Thomas et al, 1997).
TRANSGENIC ANIMAL MODELS
Several groups reported on recently established 
transgenic and gene knock-out rodent models concern­
ing PMP22, Po, Cx32, MAG, and Krox-20.
PMP22
U. Suter introduced several mouse models that 
cover a range of PMP22 gene dosages including 
animals entirely devoid of PMP22, others carrying 
only one copy, and others with an overdose of 16 or 30 
copies of the PMP22 gene (Adlkofer et al, 1995, 1997; 
Magyar et al, 1996; Huxley et al, 1996). The findings 
indicate that impairment of my elination depends on 
PMP22 gene copy numbers. In homozygous PMP22~/_ 
mice, the onset of myelination is retarded and abun­
dant tomacula develop during early postnatal develop­
ment followed by severe demyelination, axonal loss 
and functional impairment. PMP22+/'  mice are less 
affected but develop morphological features that make 
these animals an excellent model for HNPP. Con­
versely, the marked increase in PMP22 gene dosage
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caused an almost complete loss of myelin and the 
formation of numerous basal lamina onion bulbs, 
whereas moderately enhanced PMP22 gene dosage 
(approx. three-fold) in a transgenic rat model, as 
reported by K. Nave (Sereda et cil, 1996), led to 
hypomyelination and onion bulb formation that closely 
mimic that in the human CMT1A phenotype. The rat 
model further demonstrated that myelination of sen­
sory and motor nerves is differently affected. While 
motor fibers of the ventral horn are severely hypomy- 
elinated, dorsal root sensory fibers are much less 
affected.
Po
R. Martini reported on recent studies with homo- 
and heterozygous Po-deficient mouse mutants that 
develop dysmyelinating and demyelinating pheno­
types characteristic of either severely affected DSS or 
the mild CMT1B neuropathy (Giese et ah, 1992; Martini 
et ah, 1995). While Po_/~ mice develop myelination 
abnormalities including altered myelin compaction, 
hypomyelination, and degeneration of myelin and 
axons early in life, heterozygous Po-deficient mice 
initially develop quite normal myelin but show signs 
of demyelination and remyelination from postnatal 
week 16 onward. Similar to the PMP22-transgenic rats, 
motor nerves of heterozygous Po-deficient mice were 
more severely affected than sensory nerves.
Connexin 32
A Cx32 knock-out mouse was introduced by K. 
Willecke as the first animal model for CMTX (Nelles et 
ah, 1996; Anzini et ah, 1997). Since the mutants develop 
liver tumors, it was suggested that Cx32 may serve a 
yet unknown tumor suppressor function. Comments 
of neurogeneticists and neuropathologists, however, 
pointed out that CMTX patients do not suffer from an 
increased incidence of tumors. As in CMTX patients, 
neurological symptoms develop in these animals rather 
late in life. Electron microscopic examinations revealed 
that the periaxonal cytoplasm is unusually enlarged in 
both motor and sensory nerves, possibly due to lack of 
efficient connections between adaxonal and abaxonal 
cytoplasm through Schmi d t-Lanterman incisures and 
"paranodal loops/' In addition, complex interdigita- 
tions of axon and Schwann cell membranes have been 
observed. Schwann cell onion bulb formation was 
much more prominent in motor nerves compared to 
sensory nerves.
Myelin-Associated Glycoprotein (MAG)
M. Schachner presented a MAG gene knock-out 
mouse model that is mainly characterized by oligoden- 
droglia and myelin abnormalities in the CN5, but also 
shows degenerating myelin profiles and Schwann cell 
onion bulbs in the PNS of adult mice (Montag et ah, 
1994; Fruttiger et ah, 1995).
In summary, pathological alterations typical for 
particular genetic defects could be characterized, while 
dysmyelination- and demyelination-induced onion 
bulb formation may rather represent less specific 
histopathological changes possibly reflecting common 
secondary phenomena,
Krox-20
G. Levi reported on a Krox-20 gene knock-out 
mutant mouse suffering from slight trembling, lack of 
PNS myelin sheath, and deficiencies in myelin gene 
expression (Topilko et ah, 1994). Since Schwann cells in 
Krox-20-deficient mice still contact and enwrap the 
axons by approximately 1.5 turns, it was suggested 
that this Zn-finger transcription factor may regulate 
subsequent steps in myelination. Comparison of the 
expression of Krox-20 and Krox-24 in rodents demon­
strated an inverse regulation of these related transcrip­
tion factors during normal PNS development and 
myelination (upregulation of Krox-20, downregulation 
of Krox-24 in myelinating Schwann cells) as well as 
after nerve lesion (reversed patterns of Krox-20 and 
Krox-24 regulation). Additional studies on human 
CMT1A pathology revealed that Krox-24 is abnor­
mally upregulated and often coexpressed with Krox-20 
in onion bulb Schwann cells.
CELLULAR FUNCTION OF 
CMT-RELATED MYELIN PROTEINS
The presenters of this session focused on recent 
biochemical, molecular, and cell biological studies to 
characterize the biological function of known CMT- 
related myelin proteins as well as potential new 
myelin disease proteins.
PMP22
H. W. Mueller reported on the experimental proof 
for a growth modulatory function of PMP22 using 
retrovirally transduced rat Schwann cell and fibroblast 
cultures expressing altered levels of PMP22 (Zoidl et
Copyright © 1997 by Academic Press
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aL, 1995, 1997). While moderate overexpression of 
PMP22 retards progression of both cell types into and
Schwann
gnificant
signs of apoptotic cell death. 1 hese results indicate tnat 
PMP22 participates in fundamental mechanisms of cell 
growth and further demonstrate that there are cell 
type-specific differences in the ability to tolerate en­
hanced levels of PMP22. In agreement with these 
findings, C. Schneider provided further evidence for a 
link between PMP22 overexpression and programmed 
cell death using an expression plasmid microinjection
paradigm (Fabbretti et aL, 1995). In contrast to PMP22, 
the overexpression, of Po protein causes no apoptosis, 
indicating marked differences in growth-related cellu­
lar functions of myelin proteins. These data indicate an 
important role for PMP22 in regulating cell prolifera­
tion and death on one hand and cell differentiation and 
myelination on the other.
Po
P. Bolhuis presented models on the putative effects 
of various Po mutations on protein structure and 
discussed the possible impact on protein transport and 
function (Shapiro et aL, 1996). A functional test system 
for PO mutants in Drosophila Schneider cells was 
introduced by B. Rautenstrauss.
Connexin 32
R. Dermietzel summarized work of his group on the 
localization and expression of Cx32 and Cx45 in the 
PNS (Spray and Dermietzel, 1995). He showed that 
Cx32 may participate in reflexive gap junctions at 
nodes of Ranvier and Schmidt-Lanterman incisures, 
thus establishing intracellular short cuts between para- 
nodal loops and myelin layers. These gap junctions 
might shorten the time and distance required for the 
perpendicular diffusion of small molecules through 
the myelin sheath roughly by a factor of 1000 (Scherer 
et aL, 1995). Due to its localization, Cx45 is suspected to 
be involved in intercellular coupling between two 
adjacent Schwann cells at the nodal region.
L. Barrio presented a physiological study on the 
effect of CMTX-type and other Cx32 mutations on the 
coupling of paired oocytes expressing the protein 
variants (Bruzzone et aL, 1994). The degree of func­
tional coupling strongly correlated with the type of 
mutation and the length of the C-terminal portion of 
the molecule, but specific gene mutations and physi-
New Potential CMT-Related Myelin Proteins
Following the known CMT-related proteins, C. Gillen 
and M. Frank reported on the full-length cloning, 
expression, and localization of plasmolipin and rMAL / 
MVP-17, respectively (Gillen et aL, 1996; Schaeren- 
Wiemers et aL, 1995). Encoding tetraspan myelin pro­
teins, these two genes are potential candidate genes for 
CMT or related neuropathies (Magyar et aL, 1997). 
Both plasmolipin and rMAL are predominantly ex­
pressed in Schwann cells of the PNS and in the kidney, 
but to a lower degree also in oligodendrocytes of CNS 
white matter. The specific functions of these proteins 
are unknown.
PMP22 EXPRESSION IN CMT1A 
AND HNPP
In leaving animal and cell culture models, the last 
session was devoted to observations on CMT1A and 
HNPP nerve biopsies and human Schwann cell cul­
tures, O. Hanemann described the developmental 
changes in gene expression (e.g., for PMP22, p75-NGF 
receptor, NCAM), myelination (from myelinated to 
demyelinated state), cell proliferation, and onion bulb 
formation in sural nerve biopsies of young and adult 
CMT1A patients with confirmed PMP22 gene duplica­
tion (Hanemann et aL, 1996,1997). He emphasized that 
prior to apparent histological changes in myelin pro­
files, Schwann cells acquire an abnormal pattern of 
gene expression, indicating the early manifestation of a 
pathological phenotype. The abnormal molecular dif­
ferentiation is considered as a consequence of the 
specific influence of PMP22 on fundamental mecha­
nisms of cell growth as already demonstrated in vitro 
(see above). Based on his results, O. Hanemann pre­
sented a hypothesis of sequential stages in pathogen­
esis of CMT1A neuropathy leading from the initial 
PMP22 gene duplication via altered levels of PMP22 
expression, modulation of growth behavior, and abnor­
mal molecular differentiation of the Schwann cell to 
secondary events such as disturbance of myelin main­
tenance, stability, and/or turnover causing demyelin- 
ation and onion bulb formation. Since the secondary 
histopathological events are frequently observed in 
human CMT1 and in transgenic animal models as 
demonstrated during the workshop, it has been sug­
gested that the delayed events may represent the 
common terminal pathway of CMT1 neuropathies.
ological data have yet to be correlated with the severity Thus, future work will have to focus on the primary
of CMTX disease phenotypes. molecular reactions and potential altered protein inter-
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actions following abnormal expression or mutation of 
the CMT-related myelin proteins.
In the final talk, A. Schenone presented data on the 
reduced PMP22 expression levels in sural nerve biop­
sies of patients lacking one copy of the PMP22 gene 
(Schenone el ah, 1997). He demonstrated an inverse 
correlation of the clinical phenotype as defined by a 
"neuropathy disability score" with the relative amount 
of PMP22 expressed in HNPP nerves. Conversely, the 
g-ratio correlated linearly with the relative levels of 
PMP22. This work is the first human study demonstrat­
ing a dose-dependent effect of PMP22 gene dosage on 
clinical symptoms in HNPP.
CONCLUSIONS
The final discussion between the participants of the 
workshop revealed that the most important future 
CMT research directions must include a detailed com­
parison of the pathology in human and in transgenic 
animal models, the determination of structure-func- 
tion-disease correlations on the basis of the mutated 
proteins, and the search for potential partner mol­
ecules interacting with the above-mentioned myelin 
proteins. The participants agreed that a substantial 
number of useful animal and cell culture models for 
CMT and HNPP are now available. These systems are 
likely to foster further rapid progress in our under­
standing of the pathomechanisms in CMT and provide 
the basis for developing successful strategies for thera­
peutic or preventive treatment in future.
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